Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
Octave has raised $31.8M in total funding. The most recent round was Series C. The last funding was announced in March 2025.
Octave's investors include S32, Novartis, Deerfield, Hikma Ventures, Michael J. Fox Foundation.
Octave is headquartered in Menlo Park, United States.
Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
Octave is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Octave — Funding & Investors." VCBacked, March 22, 2025, https://www.vcbacked.co/company/octave-menlo-park. Accessed October 22, 2026.
VCBacked. (2025). Octave — Funding & Investors. Retrieved October 22, 2026, from https://www.vcbacked.co/company/octave-menlo-park
{{cite web |title=Octave — Funding & Investors |url=https://www.vcbacked.co/company/octave-menlo-park |website=VCBacked |access-date=October 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated